Search results
Results from the WOW.Com Content Network
Noubar Afeyan (Western Armenian: Նուպար Աֆէեան; born in 1962) is an American-Canadian entrepreneur, inventor, and philanthropist. [1] [2] He is best known for co-founding the biotechnology company Moderna, through his venture capital firm, Flagship Pioneering, and for co-founding humanitarian projects such as Aurora Prize and The Future Armenian.
The treatment of equine lameness is a complex subject. Lameness in horses has a variety of causes, and treatment must be tailored to the type and degree of injury, as well as the financial capabilities of the owner. Treatment may be applied locally, systemically, or intralesionally, and the strategy for treatment may change as healing progresses.
This sometimes leads to static laminitis, particularly if the animal is confined in a stall. [10] A notable example is the 2006 Kentucky Derby winner Barbaro. [11] Transport laminitis sometimes occurs in horses confined in a trailer or other transportation for long periods of time. Historically, the most extreme instances were of horses shipped ...
Appropriate treatment for lameness depends on the condition diagnosed, but at a minimum it usually includes rest or decreased activity and anti-inflammatory medications. Other treatment options, such as corrective shoeing, joint injections, and regenerative therapies, are pursued based on the cause of lameness and the financial limits of the owner.
The company was founded in Cambridge in 1999 by Noubar Afeyan and Ed Kania under the name NewcoGen (short for "new company generation"), but later changed its name to Flagship Ventures, and again in 2016 to Flagship Pioneering. [2]
[5] [1] The company's name is derived from the terms "modified", "RNA", and "modern". [6] [7] [8] The company's commercial products are the Moderna COVID-19 vaccine, marketed as Spikevax and a RSV vaccine, marketed as Mresvia. The company has 44 treatment and vaccine candidates, of which 37 have entered clinical trials.
LNP technology is crucial to Moderna's vaccine development efforts, and the patent ruling could increase pressure on the Cambridge, Massachusetts-based firm to pay for a license to Arbutus' patent ...
Horses are best managed by only allowing short grazing periods—less than 1 hour since they can rapidly ingest grass, [18] or confining them to a limited turn-out area or by use of a grazing muzzle. Horses with severe IR, that have recurrent laminitis, are not recommended to return to pasture. Hay low in NSC is provided in place of pasture.